Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1612 1623 1628 1629
This examiner grants 37% of resolved cases
Marcos L. Sznaidman is a very high-volume examiner in Tech Center 1600 and Art Unit 1611, with 1272 resolved cases. He has an allowance rate of 37.3%, which suggests a rigorous examination process. The interview lift is 16.2%, indicating that interviews provide a helpful boost to the chances of success.
The median days to allowance is 1304. This timeline reflects a relatively long prosecution cycle in Art Unit 1611. With 1272 resolved cases, the 37.3% allowance rate and 16.2% interview lift are very robust metrics. Practitioners should be prepared for a challenging process but can use the 1304-day median to plan their strategy in Tech Center 1600. The 16.2% lift is a key tool for overcoming the 37.3% baseline allowance rate and moving cases toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18389888 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Non-Final OA | Deciphera Pharmaceuticals, LLC |
| 18275731 | SELECTIVE ROCK2 INHIBITION FOR TREATMENT OF EDEMA AND ASSOCIATED CONDITIONS | Final Rejection | Trustees of Boston University |
| 18872672 | COMPOSITIONS COMPRISING DISODIUM 5,10-METHYLENE-(6R)-TETRAHYDROFOLATE | Non-Final OA | MERCK PATENT GMBH |
| 18028618 | USE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Final Rejection | LG CHEM, LTD. |
| 18373418 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18353069 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | Non-Final OA | The Regents of the University of California |
| 18698401 | TRICYCLIC SULFAMIDES AND SULTAMS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18691641 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Vanderbilt University |
| 18691617 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Vanderbilt University |
| 18006541 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | Final Rejection | National University of Singapore |
| 18452885 | Use of Histamine Antagonists and Glucocorticoid for Treating and Preventing Neurodegenerative Diseases | Final Rejection | City University of Hong Kong |
| 18604733 | N,N'-DIPHENYL-4,4'-BIPHENYLDICARBOXAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT | Non-Final OA | Board of Regents, The University of Texas System |
| 18363429 | NERVE AGENT DECONTAMINATING AGENTS | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18263211 | ANTIPARASITIC COMPOUNDS | Final Rejection | Intervet Inc. |
| 18415139 | METHODS FOR TREATING PAIN | Final Rejection | Xenon Pharmaceuticals Inc. |
| 18277257 | LYSOSOME-ASSOCIATED MEMBRANE PROTEIN TARGETING COMPOUNDS AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18245970 | COMBINATION COMPOSITIONS HAVING ANTI-VIRAL ACTIVITIES AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18566249 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | Non-Final OA | Janssen Pharmaceutica NV |
| 17912802 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | Final Rejection | Agency for Science, Technology and Research |
| 18191440 | METHOD FOR TREATING CEREBRAL APOPLEXY AND HYPERBILIRUBINEMIA BY COMPOUND FOR INHIBITING COMBINATION OF BILIRUBIN AND TRPM2 CHANNEL | Final Rejection | SHANGHAI SIXTH PEOPLE'S HOSPITAL |
| 18572382 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | Blueprint Medicines Corporation |
| 18207996 | TREATING HEPATITIS | Non-Final OA | Albireo AB |
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | Final Rejection | GENZYME CORPORATION |
| 18703712 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Non-Final OA | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| 18381550 | PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES | Non-Final OA | Gyre Therapeutics, Inc. |
| 17981033 | TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) | Final Rejection | Mirum Pharmaceuticals, Inc. |
| 17789399 | D-SERINE TRANSPORT MODIFIER AND SCREENING METHOD THEREOF, AND SCREENING METHOD OF D-SERINE TRANSPORTER PROTEIN | Final Rejection | National Institutes of Biomedical Innovation, Health and Nutrition |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy